Evidence map›Paper›PMID 39881179›Full record

ArticleNature communications2025

Outside-in engineering of cadherin endocytosis using a conformation strengthening antibody.

Bin Xie, Shipeng Xu, Sanjeevi Sivasankar

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Bin Xie *Biophysics Graduate Group, University of California, Davis, CA, USA.ORCID http://orcid.org/0000-0002-2305-7865
Shipeng Xu *Department of Biomedical Engineering, University of California, Davis, CA, USA.ORCID http://orcid.org/0009-0002-2895-8635
Sanjeevi SivasankarBiophysics Graduate Group, University of California, Davis, CA, USA. ssivasankar@ucdavis.edu.ORCID http://orcid.org/0000-0003-2593-0477

Funding

Staff InvestigatorsP30CA093373 · NCI · UNIVERSITY OF CALIFORNIA DAVIS · PI Gina M Dayton · 2002 to 2026
$84.9M
Mechanosensitive cadherin adhesion and its regulationR01GM133880 · NIGMS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI SIVASANKAR, SANJEEVI · 2021 to 2024
$1.5M
NCI NIH HHS P30 CA093373NIGMS NIH HHS R01 GM133880U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS) R01GM133880
6 · The paper itself

Abstract

P-cadherin, a crucial cell-cell adhesion protein which is overexpressed in numerous malignant cancers, is a popular target for drug delivery antibodies. However, molecular guidelines for engineering antibodies that can be internalized upon binding to P-cadherin are unknown. Here, we use a combination of biophysical, biochemical, and cell biological methods to demonstrate that trapping the P-cadherin extracellular region in an X-dimer adhesive conformation triggers cadherin endocytosis via an outside-in signaling mechanism. We show that the anti-cancer drug delivery monoclonal antibody CQY684, traps P-cadherin in an X-dimer conformation and strengthens this adhesive structure. Formation of stable X-dimers results in the phosphorylation of p120-catenin, a suppressor of cadherin endocytosis. This triggers the dissociation of p120-catenin from the X-dimer cytoplasmic region, which increases P-cadherin turnover and targets the cadherin-antibody complex to the lysosome. Our results establish an outside-in signaling mechanism that provides fundamental insights into how cells regulate adhesion and that can be exploited by anti-cadherin antibodies for intracellular drug delivery.

Indexed as

Antibodies, MonoclonalCadherinsEndocytosisAnimalsCateninsCell AdhesionDelta CateninHumansLysosomesPhosphorylationProtein ConformationProtein EngineeringProtein MultimerizationSignal TransductionAntibodies, MonoclonalCadherinsCateninsDelta Catenin

Identifiers

PMID39881179
PMCPMC11779849

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.